Skip to content
MARKETS / NASDAQ / PGNY
NASDAQ · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · LARGE CAP

Progyny, Inc. PGNY

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.3B
▲ 10.4% YoY
$58.5M
▲ 7.7% YoY
$191.8M
▲ 10.4% YoY
In brief

What this company does

Progyny, Inc. contracts with employers to provide women's health and family building benefits to their employees and covered dependents. It currently has contracts to provide coverage to approximately 7.2 million employees and their covered dependents, referred to in the industry as covered lives. It has grown its client base to more than 590 employers, each with at least 1,000 covered lives. As of December 31, 2025, it had 856 employees, of which 835 were full-time. It launched its fertility benefits solution in 2016 with five employer clients and has since expanded its platform to include solutions in pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing. Progyny, Inc. was incorporated in Delaware in 2008 under the name Auxogen Bioscience, Inc., changed its name to Auxogen, Inc. in 2010, and changed its name to Progyny, Inc. in 2015.

Written from the business description in Progyny, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.3B
Revenue, FY2025 · full 9-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.3 · Net income 0.1
0.5B1.0B201720182019202020212022202320242025
Compound annual growth
+17.9%
+30.2%
+24.5%
+4.7%
+29.4%
+6.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +30.2% a year over five years — but profit grew slower: net income at +4.7%, earnings per share at +6.7%.

The share count fell from 0.09B to 0.08B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 6.6% · Net 4.5%
5%10%-10%-20%201720182019202020212022202320242025
ROE
FY2025 · ROE 12.5%
10%20%30%-50%201720182019202020212022202320242025

Each USD of equity produced 12 cents of profit this year.

Cash & shareholders
USD 81.6M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 191.8
80M160M201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 81.6
100M200M201820192022202320242025

USD 81.6M in buybacks — 139% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 742.4M
EquityUSD 516.0M
CashUSD 112.2M
Current ratio2.73×

Equity funds 70% of total assets.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B1.31.21.10.80.50.30.20.10.0
Operating income $B0.10.10.10.00.00.00.0−0.0−0.0
EBITDA $B0.10.10.10.00.00.00.0−0.0−0.0
Income tax $B0.00.00.0−0.0−0.0−0.00.0−0.0−0.0
Net income $B0.10.10.10.00.10.0−0.00.0−0.0
Free cash flow $B0.20.20.20.10.00.0−0.00.0−0.0
EPS, diluted $0.650.570.620.300.660.47−0.410.04−2.37
Dividend / sh $·········
Payout %·········
ROE %12.511.113.39.731.433.0−89.5··
Shares out B0.080.090.100.090.090.090.080.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 43 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityServices-Misc Health & Allied Services, NEC
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image